$VRSK

LISS SAMUEL G sold $1.2M of VRSK

LISS SAMUEL G sold 6,765 shares of Verisk Analytics, Inc. (VRSK) at $177.63 ($1.20M total) on 2026-06-02.

Original reporting
SEC EDGAR · LISS SAMUEL G
Published Jun 4, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VRSK
Neutral
high confidence
Mentioned
$VRSK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

The disclosure updates the insider ownership record but does not introduce new operating or financial information about Verisk.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing without additional company-specific news.

03

What to watch

Insider sales often reflect diversification, tax, or pre-scheduled liquidity needs; without context on total insider activity, single transactions are noisy.

Relevance 6/10Novelty 6/10Timing: Filed June 4; sale executed June 2 (post-trade disclosure window).

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Verisk Analytics, Inc.

Company-level read

Ticker impact

$VRSKNeutralHigh confidence
Context

Verisk director Liss Samuel G sold 6,765 shares in an open-market transaction, disclosing $1.20M of insider selling on SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely muted unless part of a broader selling pattern.

Evidence & confidence

The filing is an ownership-change disclosure (Form 4) with no accompanying company event (earnings, guidance, deal, lawsuit) and no 10b5-1 plan stated.

Market effects

Minimal; this is company-specific insider activity with no sector-wide read-through provided.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly labeled as 10b5-1, it could be interpreted as a stronger near-term caution signal than routine planned selling—though still not a fundamental catalyst.

Key entities

  • Verisk Analytics, Inc.

    Subject of the insider transaction disclosure (director sale).

  • Liss Samuel G

    Director who sold 6,765 shares at $177.63/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VRSKMed

VRSK Maintained by Barclays -- Price Target Lowered to $225

Barclays maintained an Overweight rating on Verisk Analytics (VRSK) but lowered its price target from $275 to $225. The company's stock is trading at $179.17, which GuruFocus estimates is 44.4% undervalued. Verisk has a GF Score of 78/100, indicating strong profitability and growth, but lower momentum. Insider activity shows significant selling, with $2.55 million in sales over the past three months.

$VRSKMed

Is Verisk’s Q2 Beat, Buyback and AI Push Altering The Investment Case For Verisk Analytics (VRSK)?

Verisk Analytics (VRSK) reported Q2 2026 earnings and revenue above estimates, reaffirmed its 2026 outlook, and announced a $200M share repurchase. The company emphasized growth in AI and data analytics for insurance clients. Verisk projects $3.8B in revenue and $1.3B in earnings by 2029, with a 24% upside to its current price. The company's high debt levels and interest expenses remain key risks.

$VRSKMedAI 8/10

Verisk (VRSK) Down 4.7% Since Last Earnings Report: Can It Rebound?

Verisk (VRSK) shares fell 4.7% since its last earnings report. Q2 2026 earnings beat estimates at $1.98 per share, up 5.3% YoY. Revenue rose 4.3% to $806.3M. Underwriting and claims revenues increased 3.5% and 6.3% respectively. EBITDA grew 4.2% but net income declined 9.8% due to higher taxes and interest. The company maintained 2026 guidance and approved a dividend. Estimates have trended downward, with a Zacks Rank #3 (Hold).

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer